Almas Biotech Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 07-12-2024
- Paid Up Capital ₹ 0.10 M
as on 07-12-2024
- Company Age 13 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 18.32%
(FY 2016)
- Profit 288.25%
(FY 2016)
- Ebitda 506.18%
(FY 2016)
- Net Worth 39.15%
(FY 2016)
- Total Assets -27.33%
(FY 2016)
About Almas Biotech
The Company is engaged in the Trading Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Pradeep Porwal and Varsha Porwal serve as directors at the Company.
- CIN/LLPIN
U36993UP2011PTC044593
- Company No.
044593
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
02 May 2011
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- Location
Etawah, Uttar Pradesh, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Almas Biotech Private Limited offer?
Almas Biotech Private Limited offers a wide range of products and services, including Common Disease Medicines, Herbal Cough Syrup, Ayurvedic,Herbal Products & Medicine, Ayurvedic Herbal Syrups & Tonics, Ayurvedic Immunity Booster, Anti Infective Drugs & Medicines, Anti Allergic Drug, Nutraceuticals & Dietary Supplements, Multivitamin Syrup & Drops, Digestive System Drugs & Medicines.
Who are the key members and board of directors at Almas Biotech?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pradeep Porwal  | Managing Director | 02-May-2011 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Varsha Porwal | Director | 02-May-2011 | Current |
Financial Performance of Almas Biotech.
Almas Biotech Private Limited, for the financial year ended 2016, experienced significant growth in revenue, with a 18.32% increase. The company also saw a substantial improvement in profitability, with a 288.25% increase in profit. The company's net worth Soared by an impressive increase of 39.15%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Almas Biotech?
In 2016, Almas Biotech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Almas Biotech?
Unlock and access historical data on people associated with Almas Biotech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Almas Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Almas Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
